article
Shaping drug development success: how does artwork play a role?
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.
List view / Grid view
Targets
news
Promising new bioactive material to regenerate cartilage
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
article
Exploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
podcasts
Advanced techniques in toxicity testing
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
news
Reprogramming B cells to produce custom antibodies
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
article
Restoring TERT to attenuate ageing hallmarks
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
news
Spinal muscular atrophy: searching for a cure
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
news
Advancing HIV treatment with a small molecule inhibitor
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
news
Elucidating MDLC’s molecular features
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
podcasts
How mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
news
Mini-lungs enable breakthroughs in SARS-CoV-2 research
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
article
Supercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
article
The power of big data to advance genomics into clinical care
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
news
Development of a new and promising antimalarial agent
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
article
Translating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…